Drug Development
Acomplia recommended for approval in the European Union
Published in Obesity and Diabetes Week, June 5th, 2006
Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant marketing authorization in the European Union for Acomplia (rimonabant 20mg) as an adjunct to diet and exercise for the treatment of obese patients (BMI{{>=}}30kg/m2), or overweight patients (BMI>27 kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidemia.
The CHMP, comprised of regulators from all European Union countries, gave its positive opinion following a timely 1-year review of the Acomplia application. The recommendation to grant marketing authorization was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Genetics & Genomics
Chromosome 5 variations controls beta-cell mass expansion during hyperglycemia in mouse model - Obesity Complications
Obesity linked to increase in TVR after intent-to-stent percutaneous coronary intervention - Obesity Epidemiology
Mc3rKO and Mc4rKO reduced muscle oxidative metabolism and may indicate risk for weight gain - Obesity Pathogenesis
Farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice - Obesity Therapy
Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis - Adipose Tissue
Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
